| Identification | Back Directory | [Name]
3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one | [CAS]
1031206-36-6 | [Synonyms]
IMS2186
IMS2186, 10 mM in DMSO
(E)-3-(3-Hydroxy-4-methoxybenzylidene)-6-methylchroman-4-one
3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one
(3E)-2,3-Dihydro-3-[(3-Hydroxy-4-Methoxyphenyl)Methylene]-6-Methyl-4H-1-Benzopyran-4-One
4H-1-Benzopyran-4-one, 2,3-dihydro-3-[(3-hydroxy-4-methoxyphenyl)methylene]-6-methyl-, (3E)- | [Molecular Formula]
C18H16O4 | [MDL Number]
MFCD12912419 | [MOL File]
1031206-36-6.mol | [Molecular Weight]
296.32 |
| Chemical Properties | Back Directory | [Boiling point ]
535.7±50.0 °C(Predicted) | [density ]
1.286±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: >20mg/mL | [form ]
solid | [pka]
9.39±0.10(Predicted) | [color ]
white to off-white | [InChI]
1S/C18H16O4/c1-11-3-5-16-14(7-11)18(20)13(10-22-16)8-12-4-6-17(21-2)15(19)9-12/h3-9,19H,10H2,1-2H3/b13-8+ | [InChIKey]
BZCADTHMZLYKAR-MDWZMJQESA-N | [SMILES]
COc1ccc(cc1O)\C=C2/COc3ccc(C)cc3C2=O |
| Safety Data | Back Directory | [Hazard Codes ]
N | [Risk Statements ]
50/53 | [Safety Statements ]
60-61 | [RIDADR ]
UN 3077 9 / PGIII | [WGK Germany ]
3 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Aquatic Acute 1
Aquatic Chronic 1 |
| Hazard Information | Back Directory | [Uses]
IMS2186 is an anti-prileferative and anti-angiogenic compound. | [Biological Activity]
IMS2186 is an anti-proliferative and anti-angiogenic agent. Apparently IMS2186 blocks the cell cycle at G2 and inhibits the production of PGE2/TNF-α. IMS2186 inhibits cell growth in vitro in tumor cells, non-transformed fibroblasts, and retinal pigment epithelial cells. IMS2186 inhibits angiogenesis (IC50 = 0.1 μM) and cell migration. Intraocular injection of IMS2186 could be a long-lasting effective treatment for CNV (choroidal neovascularization) in AMD (age-related macular degeneration) with a reduction in scarring and related visual loss. | [in vivo]
IMS2186 (2.5 mg in 0.5 mL; intravitreal injection; single dose) has no ocular toxicity while applied to rabbit eyes[1].
IMS2186 (100 μg/eye, i.e. 2.0 μL of the solution of 50 μg/μL; single dose) shows anti-proliferative effect on laser-induced choroidal neovascularization (CNV) rat models[1].
| Animal Model: | Rat model of laser induced CNV[1] | | Dosage: | 100 μg/eye, 2.0 μL of the solution of 50 μg/μL | | Administration: | Intravitreal injection; single dose | | Result: | Resulted 30% reduction of lesion area compared to PBS in the lesion area measurement. |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|